

Bladder Cancer: Update Bulletin #2 [February 2018]

<https://marketpublishers.com/r/B47CE9ED077EN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,095.00 (Single User License)

ID: B47CE9ED077EN

Abstracts

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets.

Business Questions:

How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer?

Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward?

What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?

Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?

If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor?

Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC?

Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?

How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent?

If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC?

What are KOLs' opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed?

I would like to order

Product name: Bladder Cancer: Update Bulletin #2 [February 2018]

Product link: <https://marketpublishers.com/r/B47CE9ED077EN.html>

Price: US\$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B47CE9ED077EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970